Clinical trials: Patients With Tumor
Anemia, Lymphoma
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
This is an randomized trial to evaluate the potential benefit of erythropoietin in the treatment of anemia in patients with lymphoma after autologous hematopoietic stem cell transplantation.
- Conditions
- Anemia, Lymphoma, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03010579
- Testing
- erythropoietin, iron supplementation
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University
CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL.
- Trial name
- NCT07222579
- Testing
- Subcutaneous Blinatumomab
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Head and Neck Cancer
Quality of Life in Head and Neck Patients
Evaluation of health-related quality of life of head and neck cancer patients undergoing immunotherapy
- Trial name
- QLiHN (NCT04853862)
- Testing
- questionnaire
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Brasilia
Cancer, Carcinoma
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
- Conditions
- Cancer, Carcinoma, Head and Neck Cancer, Metastases
- Trial name
- NCT00446446
- Testing
- Panitumumab
- Volunteers
- 52 people
- Sponsor
- Amgen
Head and Neck Cancer, Radiotherapy by Tomotherapy Exclusive
Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract
This is a study whose main objective is to evaluate prospectively the proportion of patients with severe xerostomia one year after treatment with tomotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Radiotherapy by Tomotherapy Exclusive, With or Without Concurrent Chemotherapy
- Trial name
- TOQUAL (NCT01548846)
- Testing
- Tomotherapy
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Centre Francois Baclesse
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
This observational study will collect data about safety in female patients with advanced ovarian epithelial cancer with measurable residual disease after surger y.
- Trial name
- NCT02151370
- Where
- El Salvador
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
To evaluate the efficacy and safety of TAS-102 combined with bevacizumab as first-line therapy in patients with advanced colorectal cancer who could not tolerate or did not receive combined chemotherapy
- Trial name
- NCT06092242
- Testing
- Tas-102(Suyuan) combined with bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer.
- Trial name
- NCT00028886
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 17 sites in Belgium, Netherlands
- Volunteers
- 450 people
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Mantle Cell Lymphoma
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating…
- Trial name
- NCT04626791
- Testing
- Acalabrutinib, Bortezomib, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Leptomeningeal Metastasis, Leptomeningeal Disease
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in…
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer
- Trial name
- NANO-LM (NCT06417710)
- Testing
- Neurological Assessment
- Where
- 3 sites in United States, Netherlands and 1 more
- Volunteers
- 200 people
- Sponsor
- University of Zurich
Lung Cancer
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan.
- Trial name
- NCT02736513
- Testing
- AZD9291
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Soroka University Medical Center
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil) schedule in patients with hematological…
- Conditions
- Irradiated Bone Marrow, Transplant-Related Hematologic Malignancy, Leukemia, Acute, Multiple Myeloma
- Trial name
- TrRaMM-TMI (NCT03963024)
- Testing
- Conditioning treatment "Treosulfan-TMI", SCT, GvHD prophylaxis
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer, Chemotherapy
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis…
- Conditions
- Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection
- Trial name
- ADARNAT (NCT04889924)
- Testing
- Axillary Radiotherapy, Lymphadenectomy
- Where
- 61 sites in Australia, Spain
- Volunteers
- 820 people
- Sponsor
- Hospital Universitari de Bellvitge
Nausea and Vomiting, Postoperative, Liver Cancer
A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer
PONV management has been recommended as a necessary part of enhanced recovery protocols during the perioperative period, and PONV risk assessment is, therefore, a necessary first step in determining the number of medications or…
- Trial name
- NCT06356623
- Testing
- 1
- Volunteers
- 476 people
- Sponsor
- Shanghai Zhongshan Hospital
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
Multiple Myeloma, High-Risk Cancer
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Multiple myeloma is a morbid disease associated with a poor outcome, particularly those with high-risk cytogenetics. While standard therapies have modestly improved survival in these high-risk patients, myeloma remains incurable.
- Trial name
- NCT02308280
- Testing
- Bortezomib following nonmyeloablative allogeneic transplant
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
This study is to improve the first-line induction chemotherapy, by combining either Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type (Rituximab-Methotrexate-Procarbazine-Vincristine).
- Trial name
- LOC-R01 (NCT04446962)
- Testing
- Lenalidomide, Ibrutinib
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- Institut Curie
Leukemia
Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Some cancers become resistant to chemotherapy drugs. Combining cyclosporine with chemotherapy may prevent resistance to the drugs and allow the cancer cells to be killed.
- Trial name
- NCT00002688
- Testing
- cyclosporine, etoposide, mitoxantrone hydrochloride
- Where
- 12 sites in Belgium, Netherlands and 1 more
- Volunteers
- 25 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.